Neurol. praxi. 2024;25(2):146-150 | DOI: 10.36290/neu.2023.039

Central post-stroke pain

MUDr. Pavlína Nosková, Ph.D.
Centrum léčby bolesti KARIM VFN a 1. LF UK, Praha

Central Post-Stroke Pain (CPSP) is defined as a painful condition after a central stroke with a proven lesion in the central nervous system (CNS). Clinical signs appear as early as 1-3 months after the stroke, but in most affected patients it is up to 6 months. Major clinical manifestations include tension headache, pain associated with muscle spasticity and pain shoulder syndrome with possible development of complex regional pain syndrome (CRPS). The treatment combines the use of analgesics (amitriptyline, carbamazepine, gabapentinoids), physiotherapy and psychotherapeutic procedures.

Keywords: central post­‑stroke pain, central neuropatic pain, spasticity.

Received: May 18, 2023; Revised: May 18, 2023; Accepted: June 5, 2023; Prepublished online: June 5, 2023; Published: April 16, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nosková P. Central post-stroke pain. Neurol. praxi. 2024;25(2):146-150. doi: 10.36290/neu.2023.039.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cesaro P, Mann MW, Moretti JL, et al. Central pain and thalamic hyperactivity:a SPECT study. Pain. 1991;47(3):329-336. Go to original source... Go to PubMed...
    2. Corbetta D, Sarasso E, Agosta F, et al. Mirror therapy for an adult with central post­‑stroke pain: a case report. Arch Physiother. 2018;8(1):4-9. Go to original source... Go to PubMed...
    3. Frese A, Husstedt IW, Ringelstein EB, et al. Pharmacologic treatment of central poststroke pain. Clin J Pain. 2006;22:252 Go to original source... Go to PubMed...
    4. Fricová J, Hakl M. Metodické pokyny pro farmakoterapii bolesti - speciální část. Bolest. 2017;20(suppl 1):7.
    5. Fung S, Kang C. Management of central neuropathic pain involves many drugs but few have proven efficacy. Drugs a Therapy Perspectives. 2023;39:1-7. Go to original source...
    6. Garza I. Central neuropathic facial pain. Feb 2023. [cit. 19. 3. 2023]. Dostupné na: https://www.uptodate.com/contents/central­‑neuropathic­‑facial­‑pain?search=central%20post%20stroke%20pain%20syndrome & source=search_result & selectedTitle=2~12 & usage_type=default & display_rank=2.
    7. Goto T, Saitoh Y, Hashimoto N, et al. Diffusion tensor fiber tracking in patients with central post­‑stroke pain; correlation with efficacy of repetitive transcranial magnetic stimulation. Pain. 2008;140(3):509-18.
    8. Harriott AM, Karakaya F, Ayata C. Headache after ischemic stroke: a systematic review and meta­‑analysis. Neurology. 2020;94(1):e75-e86; doi: 10.1212/WNL.0000000000008591. Go to original source... Go to PubMed...
    9. Headache Classification Committee of the IHS The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1 Go to original source...
    10. Janeczková A. Neurorehabilitace nemocných po CMP ve vertebrobazilárním povodí. Bakalářská práce 2016. Univerzita Palackého Olomouc, Fakulta zdravotnických věd - Ústav fyzioterapie.
    11. Jost WH, Hefter H, Reissig A, et al. Efficacy and safety of botulinum toxin type A for the treatment of post­‑stroke arm spasticity:result of the German­‑Austrian open­‑label post­‑marketing surveillance prospective study. J Neurol Sci. 2014;337(1-2):86-90. Go to original source... Go to PubMed...
    12. Krause T, Brunecker P, Pittl S, et al. Thalamic sensory strokes with and without pai:differences in lesion patterns in the ventral posterior thalamus. J Neurol Neurosurg Psychiatry. 2012;83(8):776-784. Go to original source... Go to PubMed...
    13. Lejčko J, Kozák J, Fricová J, et al. Metodické pokyny pro farmakoterapii bolesti. Bolest. 2016;19(suppl 1).
    14. Lindenberg R, Nachtigall L, Meinzer M, et al. Defferential effects of dual and unihemispheric motor cortex stimulation in older adults. J Neurosci. 2013;33(21):9176-9183. Go to original source... Go to PubMed...
    15. McDonnell MN, Orekhov Y, Ziemann U. The role of GABAB receptors in intracortical inhibition in the human motor cortex. Exp Brain Res. 2006;173(1):86-93. Go to original source... Go to PubMed...
    16. O'Donnell MJ, Diener HC, Sacco RL, et al. Chronic pain syndrome after ischemic stroke: PRoFESS trial. Stroke. 2013;44(5):1238-1243. Go to original source... Go to PubMed...
    17. Sheldon BL, Olmsted ZT, Sabourin S, et al. Review of the treatments for central neuropathic pain. Brain Sci. 2022;12(12):1727. https://doi.org/10.3390/brainsci12121727. Go to original source... Go to PubMed...
    18. Singer J, Conigliaro A, Spina E, et al. Central poststroke pain: a systematic review. Int J Stroke. 2017;12(4):343-355. Go to original source... Go to PubMed...
    19. Státní agentura pro konopí pro léčebné použití. [cit. 19. 3. 2023]. Available from: https://www.sakl.cz/home/kontakty.
    20. Štětkářová I. Centrální poiktová bolest. Neurol. praxi. 2020;21(5):364-366. Go to original source...
    21. Treister AK, MD, Hatch MN, Cramer SC, et al. Demystifying post­‑stroke pain: from etiology to treatment. PMR. 2017;9(1):63-75.
    22. Willoch F, Schindler F, Wester HJ, et al. Central poststroke pain syndrome and reduced opioid receptor binding within pain processing circuitries. Pain. 2004;108(3):213-220. Go to original source... Go to PubMed...
    23. Widyadharma E, Tertia C, Sri Wijayanti IA, et al. Central post stroke pain: What are the new insights? Ro J Neurol. 2021;20(1). DOI: 10.37897/RJN.2021. 1. 4. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.